Back

Biohaven shares plunge 14.73% after FDA partial hold on epilepsy trials

Verifying
  • Biohaven disclosed an FDA partial hold on new-patient enrollment in BHV-7000/opakalim epilepsy trials.
  • 14.73%: Biohaven shares fell $2.21 on September 10, 2026.
  • Dosing continued for patients already randomized across the BHV-7000 program.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
Biohaven shares plunge 14.73% after FDA partial hold on epilepsy trials - CoinPost Terminal